IgA Tarpeyo denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Requires Step Therapy Before Tarpeyo — and How to Appeal

UnitedHealthcare's step-therapy (also called "fail-first") protocol for Tarpeyo (budesonide delayed-release capsules for IgA nephropathy) requires documented failure of one or more prior medications before approving coverage of Tarpeyo. In practice, this typically means demonstrating that supportive care measures and/or a prior pharmacologic agent have been tried and have not achieved adequate clinical response. The denial is issued when the plan's reviewer cannot confirm from the submitted records that all required prior steps have been completed and documented.

Many patients with IgA nephropathy have in fact already gone through exactly the steps UHC requires — the problem is usually that the documentation was not submitted in the format the reviewer needs. Step-therapy denials are frequently overturned on appeal when prior treatment history is thoroughly documented.

## Step-Therapy Override Laws

Several states have enacted step-therapy override statutes that require insurers to grant an exception when a prior step drug is contraindicated, has already been tried and failed, or would otherwise cause harm. If your plan is a fully-insured plan governed by state law, check whether your state has a step-therapy override law and cite it in your appeal. ERISA self-funded plans are generally not subject to state step-therapy laws, but the underlying federal full-and-fair review rights still apply.

## Your Federal Appeal Rights

• ACA §2719 / ERISA §503: Step-therapy denials are adverse benefit determinations subject to internal appeal and external review.
• Timeline: Internal appeal within 180 days of denial. External review for approximately four months after final internal denial. Expedited review (72-hour decision) is available if clinical urgency is documented by your nephrologist.

## Documentation to Gather Before You Appeal

1. Complete prior-treatment history — for every drug or therapy that UHC's step-therapy protocol requires as a prior step, provide: the drug name, start and end dates, doses used (from the prescribing record), the clinical response or lack thereof, and the documented reason for discontinuation or change. 2. Prescriber letter — your nephrologist should write a letter that maps your prior treatment history to each step in UHC's protocol and explains why further step-therapy is not clinically appropriate, or why you have already completed the required steps. 3. Diagnosis and severity documentation — biopsy report, lab trends, and clinical notes showing disease status and trajectory. 4. UHC step-therapy policy — obtain the specific protocol in writing so your appeal can address each step by number. 5. FDA label — the prescribing information supports the clinical rationale for using this specific agent after background therapies.

## Criteria-Mapping Structure

Build a table with each required step in UHC's protocol in the left column. In the right column, document either (a) the dates and outcomes of your prior trial of that step, or (b) your nephrologist's clinical explanation for why that step was bypassed. Attach source records for each row. A reviewer should be able to confirm every required step is addressed without searching through unstructured notes.